95 related articles for article (PubMed ID: 20605007)
1. [Impact of functional social support for abstinence after inpatient detoxification].
Mutschler J; Kobiella A; Grosshans M; Kiefer F
Neuropsychiatr; 2010; 24(2):118-24. PubMed ID: 20605007
[TBL] [Abstract][Full Text] [Related]
2. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
[TBL] [Abstract][Full Text] [Related]
3. Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence.
Colagiuri B; Morley K; Boakes R; Haber P
Psychother Psychosom; 2009; 78(3):167-71. PubMed ID: 19270472
[TBL] [Abstract][Full Text] [Related]
4. Functional social support within a medical supervised outpatient treatment program.
Mutschler J; Eifler S; Dirican G; Grosshans M; Kiefer F; Rössler W; Diehl A
Am J Drug Alcohol Abuse; 2013 Jan; 39(1):44-9. PubMed ID: 22594669
[TBL] [Abstract][Full Text] [Related]
5. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study.
Soyka M; Preuss U; Schuetz C
Drugs R D; 2002; 3(1):1-12. PubMed ID: 11881521
[TBL] [Abstract][Full Text] [Related]
6. Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
Kiefer F; Jiménez-Arriero MA; Klein O; Diehl A; Rubio G
Addict Biol; 2008 Mar; 13(1):124-9. PubMed ID: 17573782
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
[TBL] [Abstract][Full Text] [Related]
8. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
Kiefer F; Jahn H; Otte C; Naber D; Wiedemann K
Biol Psychiatry; 2006 Jul; 60(1):74-6. PubMed ID: 16483549
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological treatment of alcohol dependence. Acamprosate and naltrexone offer new approach].
Berglund M; Balldin J; Bendtsen P; Borg S; Franck J; Gustafsson L; Halldin J; Månsson M; Nilsson LH; Stolt G; Willander A
Lakartidningen; 1997 Jul; 94(30-31):2645-8. PubMed ID: 9273426
[No Abstract] [Full Text] [Related]
10. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
Kiefer F; Jahn H; Otte C; Demiralay C; Wolf K; Wiedemann K
J Psychiatr Res; 2005 Sep; 39(5):545-51. PubMed ID: 15992564
[TBL] [Abstract][Full Text] [Related]
11. Opioid antagonists for the treatment of alcohol dependence.
Yancey JR; Lumbad J
Am Fam Physician; 2011 Nov; 84(9):990-2. PubMed ID: 22046937
[No Abstract] [Full Text] [Related]
12. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
[TBL] [Abstract][Full Text] [Related]
13. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
Buri C; Moggi F; Giovanoli A; Strik W
Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
[TBL] [Abstract][Full Text] [Related]
14. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
[TBL] [Abstract][Full Text] [Related]
15. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Rösner S; Leucht S; Lehert P; Soyka M
J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Kiefer F; Helwig H; Tarnaske T; Otte C; Jahn H; Wiedemann K
Eur Addict Res; 2005; 11(2):83-91. PubMed ID: 15785069
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Snyder JL; Bowers TG
Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
[TBL] [Abstract][Full Text] [Related]
18. Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in India.
Basu D; Jhirwal OP; Mattoo SK
Am J Addict; 2005; 14(4):381-95. PubMed ID: 16188718
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological relapse prevention in alcohol and tobacco dependence].
Diehl A; Mann K
Internist (Berl); 2007 Jan; 48(1):79-84, 86-8. PubMed ID: 17122900
[TBL] [Abstract][Full Text] [Related]
20. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients.
Verheul R; Lehert P; Geerlings PJ; Koeter MW; van den Brink W
Psychopharmacology (Berl); 2005 Mar; 178(2-3):167-73. PubMed ID: 15322728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
